Abstract
A 64-year-old light-smoking woman was clinically diagnosed with lung large-cell neuroendocrine carcinoma (LCNEC) with a metastatic brain tumor. An Oncomine Dx Targeted Test using metastatic brain tissue revealed that the patient's lung cancer cells had an EML4-ALK rearrangement. Patients with LCNEC and anaplastic lymphoma kinase (ALK) gene rearrangements are rare, and there is currently no standard treatment. Based on the genomic analysis, we treated the patient with brigatinib, an ALK inhibitor. We describe here a patient with LCNEC who responded significantly to brigatinib without serious adverse events.
Keywords:
ALK rearrangement; Brigatinib; Large cell neuroendocrine carcinoma; Lung cancer; Next generation sequencing.
Copyright © 2024. Published by Elsevier B.V.
MeSH terms
-
Anaplastic Lymphoma Kinase* / antagonists & inhibitors
-
Anaplastic Lymphoma Kinase* / genetics
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / genetics
-
Brain Neoplasms / secondary
-
Carcinoma, Large Cell / drug therapy
-
Carcinoma, Large Cell / genetics
-
Carcinoma, Large Cell / pathology
-
Carcinoma, Neuroendocrine* / drug therapy
-
Carcinoma, Neuroendocrine* / genetics
-
Carcinoma, Neuroendocrine* / pathology
-
Female
-
Gene Rearrangement
-
Humans
-
Lung Neoplasms* / drug therapy
-
Lung Neoplasms* / genetics
-
Lung Neoplasms* / pathology
-
Middle Aged
-
Oncogene Proteins, Fusion* / genetics
-
Organophosphorus Compounds* / administration & dosage
-
Organophosphorus Compounds* / therapeutic use
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrimidines* / administration & dosage
-
Pyrimidines* / therapeutic use
-
Treatment Outcome
Substances
-
brigatinib
-
Organophosphorus Compounds
-
Oncogene Proteins, Fusion
-
Pyrimidines
-
EML4-ALK fusion protein, human
-
Anaplastic Lymphoma Kinase
-
ALK protein, human
-
Protein Kinase Inhibitors